ClinicalTrials.gg
TerminatedNCT05348915Updated Nov 19, 2026Results posted

A Study to Evaluate the Long-term Safety of Inclacumab Administered to Participants With Sickle Cell Disease

A Phase 3 interventional study of Inclacumab in Sickle Cell Disease, Vaso-occlusive Crisis and Vaso-occlusive Pain Episode in Sickle Cell Disease, sponsored by Pfizer. Terminated at 50 sites in 10 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.

Primary conditionVaso-Occlusive CrisesRegistry: Anemia, Sickle CellReclassifiedWhy we changed it
Registry
Anemia, Sickle Cell — the first condition term the registry derived for this study.
ClinicalTrials.gg
Vaso-Occlusive Crises
Why
  1. The study's listed conditions name Vaso-Occlusive Crises, a narrower term within Anemia, Sickle Cell.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

How we know

Why this study was terminated
Sponsor decision to terminate study based on results of parent study GBT2104-131.
Updated Nov 19, 2026Results postedStudy documents posted+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
241
Allocation
Not applicable
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 60 studies in Vaso-Occlusive Crises with a site in United States — 13 open to participants now, 15 under way, 5 of them phase 3. Vaso-Occlusive Crises · United States.

Enrollment
7th of 56
241 · median 63
Started
2022
with 6 others
Phase 3
17 of 60
3 open now
Registered
44th of 60
by date
Lead sponsor
4 of 60
Pfizer

Among the 60 studies in Vaso-Occlusive Crises with a site in United States, this one is the 7th largest by enrollment of the 56 interventional ones that give a count, is one of 7 that started in 2022, is one of 17 in phase 3, and was the 44th registered.

Vaso-Occlusive Crises

104 studies on the registry are indexed under Vaso-Occlusive Crises; 31 are open to participants now.

Browse Vaso-Occlusive Crises studies →

Open to participants now

13 of the 60 studies in Vaso-Occlusive Crises with a site in United States are open now. Recruiting first, the newest first:

8 more — sign in →

All 13 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 17 Vaso-Occlusive Crises studies recruiting now, 7 (41%) set no upper age limit and 6 (35%) stop at 75 or younger; 10 take children under 18; 1 takes healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies in Vaso-Occlusive Crises with a site in United States, or all of them as a file.
02

Study summary

This study is an open-label study to evaluate the safety of long-term administration of inclacumab in participants with sickle cell disease (SCD). Participants in this study will have completed a prior study of inclacumab.

Read the detailed description

The study will include approximately 520 adult and adolescent participants (≥ 12 years of age) with SCD.

All participants will receive inclacumab 30 mg/kg administered intravenously every 12 weeks.

03

Conditions studied

  • Sickle Cell Disease
  • Vaso-occlusive Crisis
  • Vaso-occlusive Pain Episode in Sickle Cell Disease

Browse trials for

Keywords

  • blood disorders
  • hemoglobin
  • red blood cells
  • RBCs
  • sickle-like shape
  • mutation in hemoglobin gene
  • Sickle Cell Disease
  • SCD
  • Vaso-occlusive Crisis
  • VOC
  • SCA
  • Open Label
04

In context

Vaso-Occlusive Crises Reclassified

104 studies on the registry are indexed under Vaso-Occlusive Crises; 31 are open to participants now.

This study's enrollment of 241 is above the median of 81 across 86 interventional studies indexed under Vaso-Occlusive Crises.

Browse Vaso-Occlusive Crises studies →

Lead sponsor

Pfizer is the lead sponsor of 3,338 studies on the registry; 147 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 393 (65%) have results posted.

Compared within Vaso-Occlusive Crises, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Anemia, Sickle Cell. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants who meet all the following criteria will be eligible for study enrollment:

  1. Male or female participant with SCD who participated and received study drug in a GBT-Sponsored inclacumab clinical study.
  2. Participant has completed the originating inclacumab study within 30 calendar days of the Day 1 Visit. Participants who discontinued study drug in the originating study due to a non-study drug-related AE, but who remained on study, may be eligible for treatment in this study provided the AE does not pose a risk for treatment with inclacumab.
  3. Female participants of are required to have a negative urine pregnancy test prior to dosing on Day 1.

    Note: Female participants who become of childbearing potential during the study must be willing to have a negative urine pregnancy test to remain in the study.

  4. If sexually active, female participants of childbearing potential must consistently use highly effective methods of consistently throughout the study and for at least 165 days after the last dose of study drug. If sexually active, male participants must use barrier methods of contraception until 165 days after the last dose of study drug.
  5. Participant has provided written /assent. For underage participants, both the consent of the participant's legal representative or legal guardian and the participant's assent (where applicable) must be obtained based on local requirement.

Exclusion criteria

Exclusion Criteria:

Participants meeting any of the following exclusion criteria will not be eligible for study enrollment:

  1. Female participant who is breastfeeding or pregnant.
  2. Participant had an infusions-related reaction (IRR) in the originating inclacumab clinical study.
  3. Participant withdrew consent from the originating inclacumab clinical study.
  4. Participant was lost to follow-up from the originating inclacumab clinical study.
  5. Participant has any medical, psychological, safety, or behavioral conditions that, in the opinion of the Investigator, may confound safety interpretation, interfere with compliance, or preclude .
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
241 participants (actual)

Study arms

  • Experimental
    Inclacumab 30 mg/kg

    Inclacumab 30 mg/kg administered intravenously (IV)

    Drug: Inclacumab

Interventions

  • Inclacumab will be supplied in single use 10 mL vials at a concentration of 50 mg/mL. One vial contains 500 mg of inclacumab. This is a liquid concentrate for IV infusion.

07

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment Emergent Adverse Events (TEAEs)

    An adverse event (AE) was any unfavorable and unintended sign, symptom, or disease temporally associated with the use of an investigational product, whether or not thought to be related to the investigational product. A TEAE was defined as an AE with an onset after the initiation of dosing for the first dose of study drug in current study GBT2104-133 (NCT05348915). TEAEs included both serious and all other AEs.

    Time frame: From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)

Secondary outcomes

  1. Annualized Rate of Vaso-occlusive Crises (VOCs)

    A VOC was defined as an acute episode of pain that: 1) had no medically determined cause other than a vaso-occlusive event; 2) resulted in a visit to a medical facility (hospitalization, emergency department, urgent care center, outpatient clinic, or infusion center), or resulted in a remote contact with a healthcare provider; 3) required parenteral narcotic agents, parenteral nonsteroidal anti-inflammatory drugs (NSAIDs), or an increase in treatment with oral narcotics. Annualized rate of VOC = (total number of VOC events)/(total person-years).

    Time frame: From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)

  2. Annualized Rate of VOCs That Required Admission to a Healthcare Facility and Treatment With Parenteral Pain Medication

    A VOC that required admission to a healthcare facility and treatment with parenteral pain medication was defined as an acute episode of pain that: 1) had no medically determined cause other than a vaso-occlusive event; 2) resulted in admission to a healthcare facility; 3) required parenteral narcotic agents or parenteral NSAIDs. Admission to a healthcare facility included: 1) a hospital admission or 2) an admission to an emergency room, observation unit, or infusion center for \>= 12 hours or 3) 2 visits to an emergency room, observation unit, or infusion center over a 72-hour period. Annualized rate of VOC = (total number of VOC events)/(total person-years).

    Time frame: From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)

  3. Annualized Number of Inpatient Hospitalization Days for a VOC

    A VOC was defined as an acute episode of pain that: 1) had no medically determined cause other than a vaso-occlusive event; 2) resulted in a visit to a medical facility (hospitalization, emergency department, urgent care center, outpatient clinic, or infusion center), or resulted in a remote contact with a healthcare provider; 3) required parenteral narcotic agents, parenteral NSAIDs, or an increase in treatment with oral narcotics. Annualized rate of hospitalization days = (total number of hospitalization days)/(total person-years).

    Time frame: From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)

  4. Annualized Rate of SCD-related Urgent Care Visits

    Urgent care visits included visits to the clinic, emergency room, and hospital. Analysis of this outcome measure included both VOC and non-VOC SCD-related events. Annualized rate of visits = (total number of visits)/(total person-years).

    Time frame: From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)

  5. Percentage of Total Days Missed From School or Work Due to SCD Pain Symptoms for the First 48 Weeks

    The percentage of total days missed from school or work due to SCD pain symptoms out of the total expected days of school or work attendance for the first 48 weeks of the study is presented in this outcome measure.

    Time frame: From first dose of study treatment (Day 1) up to Week 48

  6. Annualized Rate of Complicated VOCs

    A VOC was defined as an acute episode of pain that: 1) had no medically determined cause other than a vaso-occlusive event; 2) resulted in a visit to a medical facility (hospitalization, emergency department, urgent care center, outpatient clinic, or infusion center), or resulted in a remote contact with a healthcare provider; 3) required parenteral narcotic agents, parenteral NSAIDs, or an increase in treatment with oral narcotics. Complicated VOCs included acute chest syndrome (ACS), hepatic sequestration, splenic sequestration, and priapism. Annualized VOC rate = (total number of VOC events)/(total person-years).

    Time frame: From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)

  7. Annualized Rate of Red Blood Cell (RBC) Transfusions

    Annualized RBC transfusion rate = (total number of RBC transfusions)/(total person-years).

    Time frame: From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)

08

Results

Posted Nov 19, 2026

Participant flow

Participant flow — Overall Study
MilestoneInclacumab
Started241
Completed0
Not completed241
Withdrew: Lost to follow-up3
Withdrew: Physician decision6
Withdrew: Pregnancy7
Withdrew: Protocol violation1
Withdrew: Study terminated by sponsor179
Withdrew: Withdrawal by subject20
Withdrew: Other7
Withdrew: Adverse event18

Outcome measures

PrimaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs)

An adverse event (AE) was any unfavorable and unintended sign, symptom, or disease temporally associated with the use of an investigational product, whether or not thought to be related to the investigational product. A TEAE was defined as an AE with an onset after the initiation of dosing for the first dose of study drug in current study GBT2104-133 (NCT05348915). TEAEs included both serious and all other AEs.

Time frame:
From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
ParticipantsInclacumab
Number of Participants With Treatment Emergent Adverse Events (TEAEs)211
SecondaryAnnualized Rate of Vaso-occlusive Crises (VOCs)

A VOC was defined as an acute episode of pain that: 1) had no medically determined cause other than a vaso-occlusive event; 2) resulted in a visit to a medical facility (hospitalization, emergency department, urgent care center, outpatient clinic, or infusion center), or resulted in a remote contact with a healthcare provider; 3) required parenteral narcotic agents, parenteral nonsteroidal anti-inflammatory drugs (NSAIDs), or an increase in treatment with oral narcotics. Annualized rate of VOC = (total number of VOC events)/(total person-years).

Time frame:
From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
Reported as:
Number · VOC events per person-year
Annualized Rate of Vaso-occlusive Crises (VOCs)
VOC events per person-yearInclacumab
Annualized Rate of Vaso-occlusive Crises (VOCs)1.89 (1.76 to 2.03)
SecondaryAnnualized Rate of VOCs That Required Admission to a Healthcare Facility and Treatment With Parenteral Pain Medication

A VOC that required admission to a healthcare facility and treatment with parenteral pain medication was defined as an acute episode of pain that: 1) had no medically determined cause other than a vaso-occlusive event; 2) resulted in admission to a healthcare facility; 3) required parenteral narcotic agents or parenteral NSAIDs. Admission to a healthcare facility included: 1) a hospital admission or 2) an admission to an emergency room, observation unit, or infusion center for \>= 12 hours or 3) 2 visits to an emergency room, observation unit, or infusion center over a 72-hour period. Annualized rate of VOC = (total number of VOC events)/(total person-years).

Time frame:
From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
Reported as:
Number · VOC events per person-year
Annualized Rate of VOCs That Required Admission to a Healthcare Facility and Treatment With Parenteral Pain Medication
VOC events per person-yearInclacumab
Annualized Rate of VOCs That Required Admission to a Healthcare Facility and Treatment With Parenteral Pain Medication1.07 (0.97 to 1.17)
SecondaryAnnualized Number of Inpatient Hospitalization Days for a VOC

A VOC was defined as an acute episode of pain that: 1) had no medically determined cause other than a vaso-occlusive event; 2) resulted in a visit to a medical facility (hospitalization, emergency department, urgent care center, outpatient clinic, or infusion center), or resulted in a remote contact with a healthcare provider; 3) required parenteral narcotic agents, parenteral NSAIDs, or an increase in treatment with oral narcotics. Annualized rate of hospitalization days = (total number of hospitalization days)/(total person-years).

Time frame:
From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
Reported as:
Number · Hospitalization days per person-year
Annualized Number of Inpatient Hospitalization Days for a VOC
Hospitalization days per person-yearInclacumab
Annualized Number of Inpatient Hospitalization Days for a VOC7.07 (6.82 to 7.33)
SecondaryAnnualized Rate of SCD-related Urgent Care Visits

Urgent care visits included visits to the clinic, emergency room, and hospital. Analysis of this outcome measure included both VOC and non-VOC SCD-related events. Annualized rate of visits = (total number of visits)/(total person-years).

Time frame:
From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
Reported as:
Number · Visits per person-year
Annualized Rate of SCD-related Urgent Care Visits
Visits per person-yearInclacumab
Annualized Rate of SCD-related Urgent Care Visits2.53 (2.38 to 2.69)
SecondaryPercentage of Total Days Missed From School or Work Due to SCD Pain Symptoms for the First 48 Weeks

The percentage of total days missed from school or work due to SCD pain symptoms out of the total expected days of school or work attendance for the first 48 weeks of the study is presented in this outcome measure.

Time frame:
From first dose of study treatment (Day 1) up to Week 48
Reported as:
Mean · Percentage of Days
Percentage of Total Days Missed From School or Work Due to SCD Pain Symptoms for the First 48 Weeks
Percentage of DaysInclacumab
Percentage of Total Days Missed From School or Work Due to SCD Pain Symptoms for the First 48 Weeks6.2 ± 8.25
SecondaryAnnualized Rate of Complicated VOCs

A VOC was defined as an acute episode of pain that: 1) had no medically determined cause other than a vaso-occlusive event; 2) resulted in a visit to a medical facility (hospitalization, emergency department, urgent care center, outpatient clinic, or infusion center), or resulted in a remote contact with a healthcare provider; 3) required parenteral narcotic agents, parenteral NSAIDs, or an increase in treatment with oral narcotics. Complicated VOCs included acute chest syndrome (ACS), hepatic sequestration, splenic sequestration, and priapism. Annualized VOC rate = (total number of VOC events)/(total person-years).

Time frame:
From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
Reported as:
Number · VOC events per person-year
Annualized Rate of Complicated VOCs
VOC events per person-yearInclacumab
Annualized Rate of Complicated VOCs0.09 (0.06 to 0.12)
SecondaryAnnualized Rate of Red Blood Cell (RBC) Transfusions

Annualized RBC transfusion rate = (total number of RBC transfusions)/(total person-years).

Time frame:
From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
Reported as:
Number · RBC transfusions per person-year
Annualized Rate of Red Blood Cell (RBC) Transfusions
RBC transfusions per person-yearInclacumab
Annualized Rate of Red Blood Cell (RBC) Transfusions0.76 (0.68 to 0.85)

Adverse events

Collected over From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Inclacumab17/241 (7.1%)97/241 (40.2%)203/241 (84.2%)
Most frequent serious events
Showing 10 of 68
Most frequent serious events
EventInclacumab
AnaemiaBlood and lymphatic system disorders35/241
MalariaInfections and infestations23/241
Urinary tract infectionInfections and infestations8/241
PneumoniaInfections and infestations6/241
Bacterial infectionInfections and infestations5/241
InfectionInfections and infestations4/241
SepsisInfections and infestations4/241
OsteonecrosisMusculoskeletal and connective tissue disorders3/241
Haemolytic anaemiaBlood and lymphatic system disorders2/241
GastroenteritisInfections and infestations2/241
Most frequent other events
Showing 10 of 274
Most frequent other events
EventInclacumab
Sickle cell anaemia with crisisBlood and lymphatic system disorders68/241
MalariaInfections and infestations58/241
Upper respiratory tract infectionInfections and infestations42/241
HeadacheNervous system disorders42/241
ArthralgiaMusculoskeletal and connective tissue disorders26/241
Urinary tract infectionInfections and infestations24/241
AnaemiaBlood and lymphatic system disorders19/241
Pain in extremityMusculoskeletal and connective tissue disorders18/241
TonsillitisInfections and infestations17/241
Back painMusculoskeletal and connective tissue disorders17/241

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Inclacumab
Mean25.0 ± 7.36
Sex: Female, Male
Sex: Female, Male(Participants)Inclacumab
Female122
Male119
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Inclacumab
Hispanic or Latino37
Not Hispanic or Latino200
Unknown or Not Reported4
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Inclacumab
Race — African138
Race — American Indian or Alaska Native4
Race — Arab3
Race — Black or African American43
Race — Middle Eastern2
Race — White16
Race — Multiracial33
Race — Other2
09

Study locations

50 sites
  • Strada Patient Care Center, Pediatric Hematology
    Mobile, Alabama 36604, United States
  • University of South Alabama Children's and Women's Hospital
    Mobile, Alabama 36604, United States
  • South Alabama Medical Science Foundation
    Mobile, Alabama 36606, United States
  • Arkansas Children's Hospital
    Little Rock, Arkansas 72202, United States
  • UC Irvine Medical Center
    Orange, California 92868, United States
  • UConn-Neag Comprehensive Cancer Center
    Farmington, Connecticut 06030, United States
  • University of Illinois at Chicago (UIC) Clinical Research Center
    Chicago, Illinois 60612, United States
  • University of Illinois Hospital and Health Sciences System (UI Health)
    Chicago, Illinois 60612, United States
  • Brigham And Woman's Hospital
    Boston, Massachusetts 02115, United States
  • Dana-Farber Cancer Institute IDS Pharmacy
    Boston, Massachusetts 02215, United States
  • Dana-Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • University of Michigan Hospitals - Michigan Medicine
    Ann Arbor, Michigan 48109, United States
  • Jacobi Medical Center
    The Bronx, New York 10461, United States
  • Duke University Medical Center
    Durham, North Carolina 27705, United States
  • DUMC Investigational Drug Services Pharmacy
    Durham, North Carolina 27710, United States
  • McGovern Medical School at UTHealth
    Houston, Texas 77030, United States
  • UT Health Science Center at Houston - Clinical Research Unit at Memorial Hermann Hospital
    Houston, Texas 77030, United States
  • UT Physicians Comprehensive Sickle Cell Center Houston
    Houston, Texas 77030, United States
  • Instituto D'Or de Pesquisa e Ensino - Hospital São Rafael
    Salvador, Estado de Bahia 41253-190, Brazil
  • Multihemo Servicos Medicos S/A
    Recife, Pernambuco 50070-460, Brazil
  • Hospital de Clínicas de Porto Alegre
    Porto Alegre, Rio Grande do Sul 90035-903, Brazil
  • Hospital Das Clinicas da Faculdade de Medicina de Ribeirão Preto - USP
    Ribeirão Preto, São Paulo 14051-140, Brazil
  • Fundação Faculdade Regional de Medicina de São José do Rio Preto
    São José do Rio Preto, São Paulo 15090-000, Brazil
  • Instituto Estadual de Hematologia Arthur Siqueira Cavalcanti - HEMORIO
    Rio de Janeiro, 20211-030, Brazil
  • Hospital Samaritano Higienópolis/Esho Empresa De Servicos Hospitalares S.A
    São Paulo, 01232-010, Brazil
  • Casa de Saude Santa Marcelina
    São Paulo, 08270-070, Brazil
  • CEPEC-Centro de Pesquisa Clinica
    São Paulo, 08270-120, Brazil
  • Clinica de la Costa Ltda.
    Barranquilla, Atlántico 080020, Colombia
  • Sociedad de Oncología y hematología del Cesar
    Valledupar, Cesar Department 200001, Colombia
  • KEMRI/CRDR Siaya Clinical Research Annex
    Kisumu, Siaya County 40600, Kenya
  • International Cancer Institute
    Eldoret, 30100, Kenya
  • Gertrude's Children's Hospital
    Nairobi, 00100, Kenya
  • Kenya Medical Research Institute - Centre for Respiratory Disease Research
    Nairobi, 00100, Kenya
  • Strathmore University CREATES
    Nairobi, 00200, Kenya
  • American University of Beirut Medical Center
    Hamra, Beirut, Lebanon
  • Nini Hospital
    Tripoli, North Lebanon, Lebanon
  • University of Calabar Teaching Hospital
    Calabar, Cross River State 540242, Nigeria
  • National Hospital Abuja
    Abuja, Federal Capital Territory 900211, Nigeria
  • University of Abuja Teaching Hospital
    Gwagwalada, Federal Capital Territory 902101, Nigeria
  • Ahmadu Bello University Teaching Hospital
    Zaria, Kaduna State 810105, Nigeria
  • University of Nigeria Teaching Hospital
    Enugu, 460000, Nigeria
  • Barau Dikko Teaching Hospital/Kaduna State University
    Kaduna, 800212, Nigeria
  • Aminu Kano Teaching Hospital
    Kano, 700223, Nigeria
  • Department of Pediatrics, College of Medicine, Lagos University Teaching Hospital
    Lagos, 100254, Nigeria
  • Sultan Qaboos University Hospital
    Muscat, 123, Oman
  • Prince Mohammed bin Nasser Hospital
    Jizan, Southern 82943, Saudi Arabia
  • National Institute for Medical Research (NIMR)
    Dar es Salaam, 11101, Tanzania
  • Acibadem Adana Hastanesi Cocuk Hematoloji Onkoloji
    Adana, 01130, Turkey (Türkiye)
  • Baskent University Adana Appl. and Research Central, Yuregir Baskent Hospital Hematology
    Adana, 01250, Turkey (Türkiye)
  • Hacettepe University Ihsan Dogramaci Children Hospital
    Ankara, 06430, Turkey (Türkiye)
10

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

11

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2022 to primary completion in Nov 2025, 43 months.

Results were first posted in Nov 2026, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 29, 2022
First posted
Apr 27, 2022
StartActual
Mar 29, 2022
Primary completionActual
Nov 7, 2025
CompletionActual
Nov 7, 2025
Results first posted
Nov 19, 2026
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 19, 2026
Enrollment
242→241
Nov 19, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedIncidenceNumber of treatment-emergent adverse eventsParticipants With Treatment Emergent Adverse Events (TEAEs).Time frame: Day 1 through study completion, an estimate of 5 years → From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
Nov 19, 2026
Documents
Secondary outcomes
7 edited, 4 removed
What changed in the outcomes
  • EditedAnnualized rateRate of Vaso-occlusive Crises (VOCs)Time frame: Day 1 through study completion, an estimate of 5 years → From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
  • EditedAnnualized rateRate of VOCs that require admissionThat Required Admission to a healthcare facilityHealthcare Facility and treatment.Treatment With Parenteral Pain MedicationTime frame: Day 1 through study completion, an estimate of 5 years → From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
  • EditedAnnualized numberNumber of days of inpatient hospitalizationInpatient Hospitalization Days for a VOC.Time frame: Day 1 through study completion, an estimate of 5 years → From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
  • EditedAnnualized rateRate of all SCD-related urgent care visits to the clinic, emergency room, and hospital.Urgent Care VisitsTime frame: Day 1 through study completion, an estimate of 5 years → From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
  • EditedProportionPercentage of total days missed from schoolTotal Days Missed From School or work dueWork Due to SCD pain symptomsPain Symptoms for the firstFirst 48 weeks.WeeksTime frame: Day 1 through study completion, an estimate of 5 years → From first dose of study treatment (Day 1) up to Week 48
  • EditedAnnualized rateRate of complicatedComplicated VOCs.Time frame: Day 1 through study completion, an estimate of 5 years → From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
  • EditedAnnualized rateRate of Red Blood Cell (RBC transfusions.) TransfusionsTime frame: Day 1 through study completion, an estimate of 5 years → From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
  • Removedother outcomePlasma pharmacokinetic (PK) of inclacumab as assessed by population PK analysis using nonlinear mixed-effects modeling.Time frame: Day 1 through Week 48
  • Removedother outcomeIncidence of anti-drug antibodies (ADA) to inclacumab.Time frame: Day 1 through Week 48
  • Removedother outcomePD parameter (P-selectin inhibition)Time frame: Day 1 through Week 48
  • Removedother outcomePD parameter (Platelet Leukocyte Aggregation)Time frame: Day 1 through Week 48
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Results posted
    Enrollment 242→241
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedIncidenceNumber of treatment-emergent adverse eventsParticipants With Treatment Emergent Adverse Events (TEAEs).Time frame: Day 1 through study completion, an estimate of 5 years → From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
    Secondary outcomes 7 edited, 4 removed
    What changed in the outcomes
    • EditedAnnualized rateRate of Vaso-occlusive Crises (VOCs)Time frame: Day 1 through study completion, an estimate of 5 years → From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
    • EditedAnnualized rateRate of VOCs that require admissionThat Required Admission to a healthcare facilityHealthcare Facility and treatment.Treatment With Parenteral Pain MedicationTime frame: Day 1 through study completion, an estimate of 5 years → From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
    • EditedAnnualized numberNumber of days of inpatient hospitalizationInpatient Hospitalization Days for a VOC.Time frame: Day 1 through study completion, an estimate of 5 years → From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
    • EditedAnnualized rateRate of all SCD-related urgent care visits to the clinic, emergency room, and hospital.Urgent Care VisitsTime frame: Day 1 through study completion, an estimate of 5 years → From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
    • EditedProportionPercentage of total days missed from schoolTotal Days Missed From School or work dueWork Due to SCD pain symptomsPain Symptoms for the firstFirst 48 weeks.WeeksTime frame: Day 1 through study completion, an estimate of 5 years → From first dose of study treatment (Day 1) up to Week 48
    • EditedAnnualized rateRate of complicatedComplicated VOCs.Time frame: Day 1 through study completion, an estimate of 5 years → From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
    • EditedAnnualized rateRate of Red Blood Cell (RBC transfusions.) TransfusionsTime frame: Day 1 through study completion, an estimate of 5 years → From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
    • Removedother outcomePlasma pharmacokinetic (PK) of inclacumab as assessed by population PK analysis using nonlinear mixed-effects modeling.Time frame: Day 1 through Week 48
    • Removedother outcomeIncidence of anti-drug antibodies (ADA) to inclacumab.Time frame: Day 1 through Week 48
    • Removedother outcomePD parameter (P-selectin inhibition)Time frame: Day 1 through Week 48
    • Removedother outcomePD parameter (Platelet Leukocyte Aggregation)Time frame: Day 1 through Week 48
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

12

Registry details

Key details

Study ID
NCT05348915
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Apr 27, 2022
Start date
Mar 29, 2022
Primary completion
Nov 7, 2025
Completion
Nov 7, 2025
Results posted
Nov 19, 2026
Last update
Nov 19, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Inclacumab

Start the discussion